Amendments to the Claims

Please amend Claims 164, 308, 320, 332, 341 and 353-356. The Claim Listing below will replace all prior versions of the claims in the application:

Claim Listing

1-150. (Canceled)

151. (Previously presented) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein and inhibits binding of a ligand to said C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:2 or SEQ ID NO:6 and has binding specificity for a chemokine selected from the group consisting of RANTES and MCP-3.

152. (Previously presented) The antibody or antigen-binding fragment of Claim 151, wherein said C-C chemokine receptor 3 protein has binding specificity for RANTES.

153. (Previously presented) The antibody or antigen-binding fragment of Claim 151, wherein said C-C chemokine receptor 3 protein has binding specificity for MCP-3.

154. (Canceled)

155. (Previously presented) The antibody or antigen-binding fragment of Claim 151, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.

156. (Previously presented) The antibody or antigen-binding fragment of Claim 151, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.

157. (Previously presented) The antibody or antigen-binding fragment of Claim 151, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.

158. (Previously presented) The antibody or antigen-binding fragment of Claim 151, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a $F(ab')_2$ fragment and a Fv fragment.

159. (Previously presented) The antibody or antigen-binding fragment of Claim 151, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.

160. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 151 and a physiologically acceptable vehicle or carrier.

161. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 151.

162. (Previously presented) The isolated cell of Claim 161, wherein said isolated cell is a hybridoma.

163. (Previously presented) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein and inhibits binding of a ligand to said C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:4 and has binding specificity for a chemokine selected from the group consisting of RANTES and MCP-3.

164. (Currently amended) The antibody or antigen-binding fragment of Claim 163, wherein said C-C chemokine receptor 3 protein has binding specificity for RANTES.

165. (Previously presented) The antibody or antigen-binding fragment of Claim 163, wherein said C-C chemokine receptor 3 protein has binding specificity for MCP-3.

166. (Canceled)

167. (Previously presented) The antibody or antigen-binding fragment of Claim 163, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.

168. (Previously presented) The antibody or antigen-binding fragment of Claim 163, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.

169. (Previously presented) The antibody or antigen-binding fragment of Claim 163, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.

170. (Previously presented) The antibody or antigen-binding fragment of Claim 163, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a $F(ab')_2$ fragment and a Fv fragment.

171. (Previously presented) The antibody or antigen-binding fragment of Claim 163, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.

172. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 163 and a physiologically acceptable vehicle or carrier.

173. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 163.

174. (Previously presented) The isolated cell of Claim 173, wherein said isolated cell is a hybridoma.

175. (Previously presented) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein and inhibits binding of a ligand to said C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:2 or SEQ ID NO:6 and has binding specificity for eotaxin.

176. (Canceled)

177. (Previously presented) The antibody or antigen-binding fragment of Claim 175, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.

178. (Previously presented) The antibody or antigen-binding fragment of Claim 175, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.

179. (Previously presented) The antibody or antigen-binding fragment of Claim 175, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.

180. (Previously presented) The antibody or antigen-binding fragment of Claim 175, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a $F(ab')_2$ fragment and a Fv fragment.

181. (Previously presented) The antibody or antigen-binding fragment of Claim 175, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.

182. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 175 and a physiologically acceptable vehicle or carrier.

183. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 175.

184. (Previously presented) The isolated cell of Claim 183, wherein said isolated cell is a hybridoma.

185. (Previously presented) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein and inhibits binding of a ligand to said C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:4 and has binding specificity for eotaxin.

186. (Canceled)

187. (Previously presented) The antibody or antigen-binding fragment of Claim 185, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2 or the amino acid sequence of SEQ ID NO:4.

188. (Previously presented) The antibody or antigen-binding fragment of Claim 185, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.

189. (Previously presented) The antibody or antigen-binding fragment of Claim 185, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a $F(ab')_2$ fragment and a Fv fragment.

190. (Previously presented) The antibody or antigen-binding fragment of Claim 185, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.

191. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 185 and a physiologically acceptable vehicle or carrier.

192. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 185.

193. (Previously presented) The isolated cell of Claim 192, wherein said isolated cell is a hybridoma.

194. (Previously presented) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein and inhibits binding of a ligand to said C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:2 or SEQ ID NO:6 and has binding specificity for a chemokine selected from the group consisting of MCP-2 and MCP-4.

195. (Canceled)

196. (Previously presented) The antibody or antigen-binding fragment of Claim 194, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.

197. (Previously presented) The antibody or antigen-binding fragment of Claim 194, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.

198. (Previously presented) The antibody or antigen-binding fragment of Claim 194, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.

199. (Previously presented) The antibody or antigen-binding fragment of Claim 194, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a $F(ab')_2$ fragment and a Fv fragment.

200. (Previously presented) The antibody or antigen-binding fragment of Claim 194, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.

201. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 194 and a physiologically acceptable vehicle or carrier.

202. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 194.

203. (Previously presented) The isolated cell of Claim 202, wherein said isolated cell is a hybridoma.

204. (Previously presented) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein and inhibits binding of a ligand to said C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:4 and has binding specificity for a chemokine selected from the group consisting of MCP-2 and MCP-4.

205. (Previously presented) The antibody or antigen-binding fragment of Claim 204, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said C-C chemokine receptor 3 protein.

206. (Previously presented) The antibody or antigen-binding fragment of Claim 204, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2 or the amino acid sequence of SEQ ID NO:4.

207. (Previously presented) The antibody or antigen-binding fragment of Claim 204, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.

208. (Previously presented) The antibody or antigen-binding fragment of Claim 204, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a $F(ab')_2$ fragment and a Fv fragment.

209. (Previously presented) The antibody or antigen-binding fragment of Claim 204, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.

210. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 204 and a physiologically acceptable vehicle or carrier.

211. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 204.

212. (Previously presented) The isolated cell of Claim 211, wherein said isolated cell is a hybridoma.

213. (Previously presented) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein and inhibits binding of a ligand to said C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein comprises the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:6.

214. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 213 and a physiologically acceptable vehicle or carrier.

215. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 213.

216. (Previously presented) The isolated cell of Claim 215, wherein said isolated cell is a hybridoma.

217. (Previously presented) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein and inhibits binding of a ligand to said C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein comprises the amino acid sequence of SEQ ID NO:4.

218. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 217 and a physiologically acceptable vehicle or carrier.

219. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 217.

220. (Previously presented) The isolated cell of Claim 219, wherein said isolated cell is a hybridoma.

221-245. (Canceled)

246. (Previously presented) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein and inhibits binding of a ligand to said C-C

chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of the complement of SEQ ID NO: 1 or the complement of SEQ ID NO:5 under hybridization conditions of 50% formamide, 5X SSC, 1X Denhardt's solution, 10% dextran sulfate, 20 mM Tris(hydroxymethyl)aminomethane pH 7.5 and 1% SDS at 42°C, and wash conditions of 2X SSC/0.1% SDS at 42°C, and has binding specificity for eotaxin.

247. (Canceled)

248. (Previously presented) The antibody or antigen-binding fragment of Claim 246, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.

249. (Previously presented) The antibody or antigen-binding fragment of Claim 246, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.

250. (Previously presented) The antibody or antigen-binding fragment of Claim 246, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.

251. (Previously presented) The antibody or antigen-binding fragment of Claim 246, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a $F(ab')_2$ fragment and a Fv fragment.

252. (Previously presented) The antibody or antigen-binding fragment of Claim 246, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.

253. (Previously presented) The antibody or antigen-binding fragment of Claim 246, wherein said C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of the complement of SEQ ID NO:1 or the complement of SEQ ID NO:5 under hybridization conditions of 6X SSC containing 5X Denhardt's solution, 10% (w/v) dextran sulfate, 2% SDS and sheared salmon sperm DNA (100 μg/mL) at 65°C and wash conditions of 0.2X SSC, 0.5% SDS at 65°C, and has binding specificity for eotaxin.

254. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 246 and a physiologically acceptable vehicle or carrier.

255. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 246.

256. (Previously presented) The isolated cell of Claim 255, wherein said isolated cell is a hybridoma.

257. (Previously presented) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein and inhibits binding of a ligand to said C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of the complement of SEQ ID NO:3 under hybridization conditions of 50% formamide, 5X SSC, 1X Denhardt's solution, 10% dextran sulfate, 20 mM Tris(hydroxymethyl)aminomethane pH 7.5 and 1% SDS at 42°C, and wash conditions of 2X SSC/0.1% SDS at 42°C, and has binding specificity for eotaxin.

258. (Canceled)

259. (Previously presented) The antibody or antigen-binding fragment of Claim 257, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein

comprising the amino acid sequence of SEQ ID NO:2 or the amino acid sequence of SEQ ID NO:4.

260. (Previously presented) The antibody or antigen-binding fragment of Claim 257, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.

261. (Previously presented) The antibody or antigen-binding fragment of Claim 257, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a $F(ab')_2$ fragment and a Fv fragment.

262. (Previously presented) The antibody or antigen-binding fragment of Claim 257, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.

263. (Previously presented) The antibody or antigen-binding fragment of Claim 257, wherein said C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of the complement of SEQ ID NO:3 under hybridization conditions of 6X SSC containing 5X Denhardt's solution, 10% (w/v) dextran sulfate, 2% SDS and sheared salmon sperm DNA (100 μg/mL) at 65°C and wash conditions of 0.2X SSC, 0.5% SDS at 65°C, and has binding specificity for eotaxin.

264. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 257 and a physiologically acceptable vehicle or carrier.

265. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 257.

266. (Previously presented) The isolated cell of Claim 265, wherein said isolated cell is a hybridoma.

267-291. (Canceled)

292. (Previously presented) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein and inhibits binding of a ligand to said C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein is encoded by SEQ ID NO:1 or SEQ ID NO:5.

293. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 292 and a physiologically acceptable vehicle or carrier.

294. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 292.

295. (Previously presented) The isolated cell of Claim 294, wherein said isolated cell is a hybridoma.

296. (Previously presented) An antibody or antigen-binding fragment thereof that specifically binds a C-C chemokine receptor 3 protein and inhibits binding of a ligand to said C-C chemokine receptor 3 protein, wherein said C-C chemokine receptor 3 protein is encoded by SEQ ID NO:3.

297. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 296 and a physiologically acceptable vehicle or carrier.

298. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 296.

299. (Previously presented) The isolated cell of Claim 298, wherein said isolated cell is a hybridoma.

300. (Previously presented) Antibody 7B11 (ATCC Accession No. HB-12195) or an antigen-binding fragment thereof.

301. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 300 and a physiologically acceptable vehicle or carrier.

302. (Previously presented) The hybridoma cell line deposited under ATCC Accession No. HB-12195.

303. (Previously presented) An antibody or antigen-binding fragment thereof having binding specificity for a C-C chemokine receptor 3, wherein said antibody or antigen-binding fragment comprises the light chain CDRs (CDR1, CDR2 and CDR3) and the heavy chain CDRs (CDR1, CDR2 and CDR3) of monoclonal antibody 7B11 (ATCC Accession No. HB-12195).

304. (Previously presented) The antibody or antigen-binding fragment of Claim 303 wherein said antibody or fragment is a humanized immunoglobulin or antigen-binding fragment thereof comprising the light chain CDRs (CDR1, CDR2 and CDR3) and the heavy chain CDRs (CDR1, CDR2 and CDR3) of monoclonal antibody 7B11 (ATCC Accession No. HB-12195) and a human framework region.

305. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 303 and a physiologically acceptable vehicle or carrier.

306. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 303.

307. (Previously presented) The isolated cell of Claim 306, wherein said isolated cell is a hybridoma.

308. (Currently amended) An antibody or antigen-binding fragment thereof having binding specificity for a C-C chemokine receptor 3 protein, wherein said antibody or antigen-binding fragment binds a C-C chemokine receptor 3 protein that is expressed on the surface of a whole cell, and wherein said C-C chemokine receptor 3 protein has at least

90% amino acid sequence identity with SEQ ID NO:2 or SEQ ID NO:6 and has binding specificity for a chemokine selected from the group consisting of RANTES and MCP-3.

309. (Previously presented) The antibody or antigen-binding fragment of Claim 308, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said C-C chemokine receptor 3 protein.

310. (Previously presented) The antibody or antigen-binding fragment of Claim 309, wherein said ligand is selected from the group consisting of RANTES and MCP-3.

311. (Previously presented) The antibody or antigen-binding fragment of Claim 308, wherein said C-C chemokine receptor 3 protein comprises SEQ ID NO:2.

312. (Previously presented) The antibody or antigen-binding fragment of Claim 308, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.

313. (Previously presented) The antibody or antigen-binding fragment of Claim 308, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.

314. (Previously presented) The antibody or antigen-binding fragment of Claim 308, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.

315. (Previously presented) The antibody or antigen-binding fragment of Claim 308, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a $F(ab')_2$ fragment and a Fv fragment.

316. (Previously presented) The antibody or antigen-binding fragment of Claim 308, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.

317. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 308 and a physiologically acceptable vehicle or carrier.

318. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 308.

319. (Previously presented) The isolated cell of Claim 318, wherein said isolated cell is a hybridoma.

320. (Currently amended) An antibody or antigen-binding fragment thereof having binding specificity for a C-C chemokine receptor 3, wherein said antibody or antigen-binding fragment binds a C-C chemokine receptor 3 protein that is expressed on the surface of a whole cell, and wherein said C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:2 or SEQ ID NO:6 and has binding specificity for eotaxin.

321. (Previously presented) The antibody or antigen-binding fragment of Claim 320, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said C-C chemokine receptor 3 protein.

322. (Previously presented) The antibody or antigen-binding fragment of Claim 321, wherein said ligand is selected from the group consisting of RANTES, MCP-3 and eotaxin.

323. (Previously presented) The antibody or antigen-binding fragment of Claim 320, wherein said C-C chemokine receptor 3 protein comprises SEQ ID NO:2.

324. (Previously presented) The antibody or antigen-binding fragment of Claim 320, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.

325. (Previously presented) The antibody or antigen-binding fragment of Claim 320, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.

326. (Previously presented) The antibody or antigen-binding fragment of Claim 320, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.

327. (Previously presented) The antibody or antigen-binding fragment of Claim 320, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a $F(ab')_2$ fragment and a Fv fragment.

328. (Previously presented) The antibody or antigen-binding fragment of Claim 320, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.

329. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 320 and a physiologically acceptable vehicle or carrier.

330. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 320.

331. (Previously presented) The isolated cell of Claim 330, wherein said isolated cell is a hybridoma.

332. (Currently amended) An antibody or antigen-binding fragment thereof having binding specificity for a C-C chemokine receptor 3 protein, wherein said antibody or antigen-binding fragment binds a C-C chemokine receptor 3 protein that is expressed on the surface of a whole cell, and wherein said C-C chemokine receptor 3 protein has at least 90% amino acid sequence identity with SEQ ID NO:2 or SEQ ID NO:6 and has binding specificity for a chemokine selected from the group consisting of MCP-2 and MCP-4.

333. (Previously presented) The antibody or antigen-binding fragment of Claim 332, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said C-C chemokine receptor 3 protein.

334. (Previously presented) The antibody or antigen-binding fragment of Claim 333, wherein said ligand is selected from the group consisting of RANTES, MCP-3, eotaxin, MCP-2 and MCP-4.

335. (Previously presented) The antibody or antigen-binding fragment of Claim 332, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.

336. (Previously presented) The antibody or antigen-binding fragment of Claim 332, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a $F(ab')_2$ fragment and a Fv fragment.

337. (Previously presented) The antibody or antigen-binding fragment of Claim 332, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.

338. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 332 and a physiologically acceptable vehicle or carrier.

339. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 332.

340. (Previously presented) The isolated cell of Claim 339, wherein said isolated cell is a hybridoma.

341. (Currently amended) An antibody or antigen-binding fragment thereof having binding specificity for a C-C chemokine receptor 3, wherein said antibody or antigen-binding fragment binds a C-C chemokine receptor 3 protein that is expressed on the surface of a whole cell, and wherein said C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of the complement of SEQ ID NO: 1 or the complement of SEQ ID NO:5 under hybridization conditions of 50% formamide, 5X SSC, 1X Denhardt's solution, 10% dextran sulfate, 20 mM Tris(hydroxymethyl)aminomethane pH 7.5 and 1% SDS at 42°C, and wash conditions of 2X SSC/0.1% SDS at 42°C, and has binding specificity for eotaxin.

342. (Previously presented) The antibody or antigen-binding fragment of Claim 341, wherein said antibody or antigen-binding fragment inhibits binding of a ligand to said C-C chemokine receptor 3 protein.

343. (Previously presented) The antibody or antigen-binding fragment of Claim 342, wherein said ligand is selected from the group consisting of RANTES, MCP-3 and eotaxin.

344. (Previously presented) The antibody or antigen-binding fragment of Claim 341, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:2.

345. (Previously presented) The antibody or antigen-binding fragment of Claim 341, wherein said antibody or antigen-binding fragment can compete with monoclonal antibody 7B11 (ATCC Accession No. HB-12195) for binding to a C-C chemokine receptor 3 protein comprising the amino acid sequence of SEQ ID NO:4.

346. (Previously presented) The antibody or antigen-binding fragment of Claim 341, wherein said C-C chemokine receptor 3 protein is a human C-C chemokine receptor 3 protein.

347. (Previously presented) The antibody or antigen-binding fragment of Claim 341, wherein said antibody or antigen-binding fragment is an antigen-binding fragment selected from the group consisting of a Fab fragment, a Fab' fragment, a $F(ab')_2$ fragment and a Fv fragment.

348. (Previously presented) The antibody or antigen-binding fragment of Claim 341, wherein said antibody or antigen-binding fragment is a humanized antibody, a chimeric antibody, an antigen-binding fragment of a humanized antibody, or an antigen-binding fragment of a chimeric antibody.

349. (Previously presented) The antibody or antigen-binding fragment of Claim 341, wherein said C-C chemokine receptor 3 protein is encoded by a nucleic acid that hybridizes to a second nucleic acid consisting of the nucleotide sequence of the complement of SEQ ID NO:1 or the complement of SEQ ID NO:5 under hybridization conditions of 6X SSC containing 5X Denhardt's solution, 10% (w/v) dextran sulfate, 2% SDS and sheared salmon sperm DNA (100 μg/mL) at 65°C and wash conditions of 0.2X SSC, 0.5% SDS at 65°C, and has binding specificity for eotaxin.

350. (Previously presented) A composition comprising the antibody or antigen-binding fragment of Claim 341 and a physiologically acceptable vehicle or carrier.

351. (Previously presented) An isolated cell that produces the antibody or antigen-binding fragment of Claim 341.

352. (Previously presented) The isolated cell of Claim 351, wherein said isolated cell is a hybridoma.

353. (Currently amended) An antibody or antigen-binding fragment thereof having binding specificity for a C-C chemokine receptor 3 protein, wherein said antibody or antigen-

binding fragment binds a C-C chemokine receptor 3 protein that is expressed on the surface of a whole cell, and wherein said C-C chemokine receptor 3 protein comprises the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:6.

354. (Currently amended) An antibody or antigen-binding fragment thereof having binding specificity for a C-C chemokine receptor 3 protein, wherein said antibody or antigen-binding fragment binds a C-C chemokine receptor 3 protein that is expressed on the surface of a whole cell, and wherein said C-C chemokine receptor 3 protein comprises the amino acid sequence of SEQ ID NO:4.

355. (Currently amended) An antibody or antigen-binding fragment thereof having binding specificity for a C-C chemokine receptor 3 protein, wherein said antibody or antigen-binding fragment binds a C-C chemokine receptor 3 protein that is expressed on the surface of a whole cell, and wherein said C-C chemokine receptor 3 protein is encoded by SEQ ID NO:1 or SEQ ID NO:5.

356. (Currently amended) An antibody or antigen-binding fragment thereof having binding specificity for a C-C chemokine receptor 3 protein, wherein said antibody or antigen-binding fragment binds a C-C chemokine receptor 3 protein that is expressed on the surface of a whole cell, and wherein said C-C chemokine receptor 3 protein is encoded by SEQ ID NO:3.